The San Francisco Vaccine and Prevention Unit (SFVPU) provides scientific leadership, capacity to recruit study volunteers into vaccine and non-vaccine prevention trials, innovative methods for community engagement in research, and mentorship of junior investigators. We will test vaccine and prevention strategies likely to have the greatest impact in reducing HIV infection in the United States and globally through our affiliation with the HIV Vaccine Trials Network and the HIV Prevention Trials Network. The SFVPU is housed in the San Francisco Department of Public Health, using a non-profit fiscal pass-through agency, Public Health Foundation Enterprises, to provide fiscal and human-resource management. ADMINISTRATIVE COMPONENT:

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-AR-A (M1))
Program Officer
Sachau, Bill R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Public Health Foundation Enterprises
City of Industry
United States
Zip Code
Latkin, Carl A; Van Tieu, Hong; Fields, Sheldon et al. (2017) Social Network Factors as Correlates and Predictors of High Depressive Symptoms Among Black Men Who Have Sex with Men in HPTN 061. AIDS Behav 21:1163-1170
Janes, Holly E; Cohen, Kristen W; Frahm, Nicole et al. (2017) Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. J Infect Dis 215:1376-1385
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60
Buchbinder, Susan P; Liu, Albert Y (2015) CROI 2015: Advances in HIV Testing and Prevention Strategies. Top Antivir Med 23:8-27
Irvin, Risha; Vallabhaneni, Snigdha; Scott, Hyman et al. (2015) Examining levels of risk behaviors among black men who have sex with Men (MSM) and the association with HIV acquisition. PLoS One 10:e0118281
Luetkemeyer, Anne F; Rosenkranz, Susan L; Lu, Darlene et al. (2015) Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis 60:1860-3
Cillo, Anthony R; Hilldorfer, Benedict B; Lalama, Christina M et al. (2015) Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. AIDS 29:2121-9
Cohen, Stephanie E; Vittinghoff, Eric; Doblecki-Lewis, Susanne et al. (2015) Authors' Reply: Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States. J Acquir Immune Defic Syndr 70:e33-5
Scott, Hyman M; Irvin, Risha; Wilton, Leo et al. (2015) Sexual Behavior and Network Characteristics and Their Association with Bacterial Sexually Transmitted Infections among Black Men Who Have Sex with Men in the United States. PLoS One 10:e0146025
Cohen, Stephanie E; Vittinghoff, Eric; Bacon, Oliver et al. (2015) High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr 68:439-48

Showing the most recent 10 out of 35 publications